---
title: "Asensus Surgical (ASXC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ASXC.US.md"
symbol: "ASXC.US"
name: "Asensus Surgical"
industry: "Health Care Equipment"
datetime: "2026-05-20T12:56:55.024Z"
locales:
  - [en](https://longbridge.com/en/quote/ASXC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ASXC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ASXC.US.md)
---

# Asensus Surgical (ASXC.US)

## Company Overview

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company’s products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: D (0.71)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 176 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 39.05% |  |
| Net Profit YoY | -5.15% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 9850000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -334.02% | E |
| Profit Margin | -850.75% | E |
| Gross Margin | -20.48% | E |
| Revenue YoY | 39.05% | A |
| Net Profit YoY | -5.15% | C |
| Total Assets YoY | -50.87% | E |
| Net Assets YoY | -118.42% | E |
| Cash Flow Margin | -11.75% | D |
| OCF YoY | 39.05% | A |
| Turnover | 0.17 | D |
| Gearing Ratio | 129.42% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Asensus Surgical",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "39.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-5.15%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "9850000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-334.02%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-850.75%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-20.48%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "39.05%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-5.15%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-50.87%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-118.42%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-11.75%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "39.05%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "129.42%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ASXC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ASXC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ASXC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ASXC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**